Denmark

Denmark's medical cannabis pilot programme launched in January 2018, allowing doctors to prescribe unauthorised products. The programme was initially due to end December 2021 but has been extended continuously.

In November 2024, the Danish Government decided to make the programme permanent, establishing a lasting framework for cultivation, manufacturing, and exports.

The Danish Medicines Agency oversees licensing for cultivation, bulk and primary product production, extract manufacturing, and exports. Companies need separate permits for bulk/primary products versus intermediate products.

All manufacturers are subject to continuous inspections for EU-GMP compliance.

Who can prescribe: All doctors under the pilot scheme.

Approved conditions:

• Painful spasms associated with multiple sclerosis or spinal cord damage
• Nausea from chemotherapy
• Neuropathic pain from neurological disorders

Reimbursement:

• Terminally ill patients: fully reimbursed
• Non-terminal patients: 50% reimbursement up to DKK 20,000 (~€2,700) per year; costs above that threshold are paid entirely by patients

Flower products available: 5, all from Bedrocan (Netherlands). Price range: €8.09–€22.21 per gram.

• Suppliers: Bedica, Bediol, Bedrocan (via CannGros or Scanleaf)

Extract products available: 6, including CBD, THC, and balanced formulations. Price range: €80–€270 per unit (30ml).

• Suppliers: Stenocare, Scanleaf, Balancial

Flower imports: All 5 flower products imported from the Netherlands.

Extract imports: 4 from Canada, 1 from New Zealand, 1 produced domestically.

Export performance: Denmark exported over 7 tonnes to Germany in 2024, making it one of Germany's top suppliers after Canada and Portugal. Other export markets include Australia (1.7 tonnes in 2023, growing) and the UK (85 kg in 2023, rising to 243 kg in 2024).

Domestic licensed producers (as of 2025): 8 companies licensed for bulk and primary product cultivation/production; 9 licensed for intermediate products.